APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer
- Conditions
- Oligometastatic Hormone Sensitive Prostate Cancer
- Interventions
- Combination Product: SBRT on all sites of metastatic disease+Apalutamide
- Registration Number
- NCT05717660
- Lead Sponsor
- Azienda Ospedaliero-Universitaria Careggi
- Brief Summary
Final results from TITAN trial showed that apalutamide plus ADT improved OS in a population of patients with metastatic hormone sensitive prostate cancer (mHSPC), if compared to ADT alone. However, stereotactic body radiotherapy (SBRT) showed to improve outcomes of oligometastatic patients if compared to systemic therapy alone within modern randomized trial, including a mixed cohort of different pathologies. However, there are no trials specifically exploring the benefit offered by SBRT in oligometastatic mHSPC treated with Apalutamide if compared to Apalutamide alone associated to Androgen deprivation therapy. Thus, a randomized trial was designed to test specifically the hypotesis that SBRT will improve outcome in a selected population of oligometastatic mHSPC treated with Apalutamide and ADT, undergoing baseline staging according to local reimbursability.
- Detailed Description
Prospective Phase II randomized superiority study, open label, multicentric. Patients with Oligometastatic hormone sensitive prostate cancer defined as presence of ≤ 5 non-visceral metastatic lesions and treated with androgen deprivation treatment associated with Apalutamide will be randomized to receive standard systemic treatment alone or concomitant SBRT on all sites of metastatic disease.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Male
- Target Recruitment
- 180
- Patients who have signed written informed consent
- Adult patients ≥ 18 years
- Oligometastatic hormone sensitive prostate cancer defined as presence of ≤ 5 non-visceral metastatic lesions *, **
- All lesions must be amenable to SBRT in judgment of treating radiation oncologist ***
- Patients with metastatic recurrence after previous radical prostatectomy or definitive radiotherapy will be included in the trial, provided that radical approach on prostate is administered
- Androgen deprivation therapy (ADT) started ≤ 6 months before enrollment
- Patients should be eligible to Apalutamide treatment
- Presence of visceral disease
- De novo metastatic disease
- Any contraindication to the use of Apalutamide
- Any condition for which, in the opinion of the treating physician, SBRT should not be proposed or could be contraindicated
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment SBRT on all sites of metastatic disease+Apalutamide Androgen Deprivation therapy and Apalutamide and SBRT on all sites of metastatic disease Control SBRT on all sites of metastatic disease+Apalutamide Androgen Deprivation therapy and Apalutamide
- Primary Outcome Measures
Name Time Method Complete biochemical response 6 months after treatment start. Rate of patients with complete biochemical response (PSA \< 0.2 ng/ml)
- Secondary Outcome Measures
Name Time Method Health related quality of life 2 years after treatment Measured with EORTC QLQ-PR25 questionnaire
Cancer Specific Survival 2 years after treatment Time between randomization and death from prostate cancer
Freedom from biochemical progression 2 years after treatment Biochemical progression defined according to Prostate Cancer Working Group Criteria
Freedom from radiological progression 2 years after treatment radiological progression defined according to Prostate Cancer Working Group Criteria
Rate of adverse events 2 years after treatment measured according to Common Terminology Criteria for Adverse Events
Overall Survival 2 years after treatment Time between randomization and death from any cause
Trial Locations
- Locations (1)
AOU Careggi Radiation Oncology Unit
🇮🇹Florence, Italy